Vyvanse Tablet, Chewable
Product Images NDC 59417-116

Product Visual Gallery

This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Vyvanse (NDC 59417-116). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Takeda Pharmaceuticals America, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Vyvanse 01)

Chemical structure diagram of lisdexamfetamine dimesylate, the active ingredient in Vyvanse capsules. The structure shows the molecular arrangement including phenyl and amine groups along with dimesylate counterions.*

FDA Label Image

Figure 1 (Vyvanse 02)

A forest plot chart illustrating the pharmacokinetic fold change and 90% confidence intervals for lisdexamfetamine dimesylate across various special populations. Categories include gender, age groups 65-74 and 75+, renal impairment levels (mild, moderate, severe), and end stage renal disease, with pharmacokinetic parameters Cmax and AUC shown relative to a reference value of 1.0.*

FDA Label Image

Figure 2 (Vyvanse 03)

A forest plot chart showing the fold change and 90% confidence intervals for pharmacokinetic parameters Cmax and AUC of lisdexamfetamine dimesylate when coadministered with guanfacine, venlafaxine, or omeprazole. The x-axis represents change relative to reference, ranging from 0.0 to 2.0.*

FDA Label Image

Figure 3 (Vyvanse 04)

A pharmacokinetic chart showing fold changes and 90% confidence intervals for various interacting drugs including Guanfacine, Venlafaxine, and substrates of CYP1A2, CYP2D6, CYP2C19, and CYP3A. The plot compares Cmax and AUC values relative to a reference, illustrating how each drug interaction affects these pharmacokinetic parameters.*

FDA Label Image

Figure 4 (Vyvanse 05)

A line graph comparing LS Mean (SE) SKAMP Deportment Scores over time post-dose between Vyvanse and placebo. The x-axis represents time in hours post-dose from 0 to 13, and the y-axis shows LS Mean (SE) SKAMP Deportment Scores ranging from 0.0 to 2.0. Vyvanse is depicted with a solid line showing lower scores initially, then gradually increasing over time. Placebo is shown with a dashed line, generally higher scores initially, peaking around 5 hours, then declining slightly.*

FDA Label Image

Figure 5 (Vyvanse 06)

A line graph comparing the proportion of subjects with relapse or treatment failure over time (days after randomization) between Vyvanse and placebo groups. The x-axis shows time in days, and the y-axis shows the percentage of affected subjects. Vyvanse is represented by a solid line with consistently lower relapse rates than the placebo's dashed line, which rises sharply.*

FDA Label Image

Figure 6 (Vyvanse 07)

A line graph depicting LS Mean (SE) PERMP Total Scores over time post-dose (hours) comparing Vyvanse and placebo. Two lines with error bars show score changes from approximately -0.5 to 14 hours post-dose, with Vyvanse maintaining higher scores than placebo throughout the period.*

FDA Label Image

Figure 7 (Vyvanse 08)

A Kaplan-Meier curve comparing the proportion of subjects with relapse or treatment failure over time following randomization for Vyvanse versus placebo. The x-axis represents time in days, and the y-axis shows the proportion of subjects experiencing relapse or treatment failure as a percentage. The curve for Vyvanse remains notably lower than placebo across the duration.*

FDA Label Image

Figure 8 (Vyvanse 09)

A relapse proportion over time graph comparing Vyvanse and placebo from a clinical study. The y-axis shows the proportion of subjects with relapse (%) and the x-axis shows days after randomization up to about 209 days. Vyvanse shows a consistently lower relapse rate compared to placebo. Below the graph is a table showing the number of subjects at risk over time in each group: Vyvanse and placebo.*

FDA Label Image

Principal Display Panel (10 mg Capsule Bottle Label)

The label for Vyvanse capsules contains lisdexamfetamine dimesylate as the active ingredient, with a strength of 10 mg. It is labeled for oral use and prescription only. The label includes dispensing instructions, storage conditions, and manufacturer information from Takeda Pharmaceuticals America, Inc. The package contains 100 capsules and displays the NDC 59417-101-10 along with a barcode.*

FDA Label Image

Principal Display Panel (20 mg Capsule Bottle Label)

Vyvanse 20 mg capsules label showing the active ingredient lisdexamfetamine dimesylate. The label includes NDC 59417-102-10, states the quantity of 100 capsules, and is manufactured by Takeda Pharmaceuticals America, Inc. It contains storage instructions, barcode, and a caution indicating Rx only.*

FDA Label Image

Principal Display Panel (30 mg Capsule Bottle Label)

Label for Vyvanse 30 mg capsules containing lisdexamfetamine dimesylate, manufactured by Takeda Pharmaceuticals America, Inc. This prescription oral capsule package contains 100 capsules. The label includes storage instructions, NDC 59417-103-10, barcode, and a notice to see the package insert for patient information.*

FDA Label Image

Principal Display Panel (40 mg Capsule Bottle Label)

Vyvanse 40 mg capsules packaging label showing the proprietary name, generic name lisdexamfetamine dimesylate, dosage strength of 40 mg, and quantity of 100 capsules. The label includes storage instructions, pharmacist medication guide note, NDC 59417-104-10, barcode, and the Takeda Pharmaceuticals America, Inc. logo and information.*

FDA Label Image

Principal Display Panel (50 mg Capsule Bottle Label)

Vyvanse 50 mg capsules label from Takeda Pharmaceuticals America, Inc. The label shows the proprietary name Vyvanse with the generic name lisdexamfetamine dimesylate. It specifies 50 mg dosage strength and includes storage instructions, a barcode, NDC 59417-105-10, and a statement that each capsule contains 50 mg equivalent of lisdexamfetamine.*

FDA Label Image

Principal Display Panel (60 mg Capsule Bottle Label)

Label for Vyvanse 60 mg capsules containing lisdexamfetamine dimesylate by Takeda Pharmaceuticals America, Inc. The label includes dosage strength, NDC number 59417-106-10, barcode, quantity of 100 capsules, and storage information. It specifies the product as prescription only.*

FDA Label Image

Principal Display Panel (70 mg Capsule Bottle Label)

Label for Vyvanse capsules, each containing 70 mg of lisdexamfetamine dimesylate. The label indicates a package size of 100 capsules and includes the NDC 59417-107-10. It identifies Takeda Pharmaceuticals America, Inc. as the labeler and provides storage instructions and a notice to see the package insert for additional information.*

FDA Label Image

Principal Display Panel (10 mg Tablet Bottle Label)

Vyvanse 10 mg chewable tablets packaging label, showing a round white tablet marked with '10'. The label indicates 100 chewable tablets per container, the active ingredient lisdexamfetamine dimesylate, and instructions to chew tablets completely before swallowing. It includes storage conditions and is distributed by Takeda Pharmaceuticals America, Inc.*

FDA Label Image

Principal Display Panel (20 mg Tablet Bottle Label)

Vyvanse 20 mg chewable tablets packaging label from Takeda Pharmaceuticals America, Inc. The label includes storage instructions, a hexagonal white tablet imprinted with '20', quantity of 100 chewable tablets, and dosage form as chewable tablets for oral use. It also states the active ingredient lisdexamfetamine dimesylate per tablet and the Rx only designation.*

FDA Label Image

Principal Display Panel (30 mg Tablet Bottle Label)

Vyvanse 30 mg chewable tablets label showing lisdexamfetamine dimesylate as the active ingredient. The label indicates a package containing 100 chewable tablets. It instructs to chew tablets completely before swallowing and notes Rx only. The label includes storage instructions, distributor information for Takeda Pharmaceuticals America, Inc., and a barcode with the NDC 59417-117-01.*

FDA Label Image

Principal Display Panel (40 mg Tablet Bottle Label)

Vyvanse 40 mg chewable tablets packaging label showing the product name, active ingredient lisdexamfetamine dimesylate, dosage strength of 40 mg, and quantity of 100 chewable tablets. Label includes storage instructions, distributor Takeda Pharmaceuticals America, Inc., visual depiction of a white tablet marked '40', and barcode with NDC 59417-118-01.*

FDA Label Image

Principal Display Panel (50 mg Tablet Bottle Label)

Vyvanse 50 mg chewable tablets label showing the product name, active ingredient lisdexamfetamine dimesylate, and strength of 50 mg. The label includes an image of a white, round chewable tablet marked with '50', indicates a package size of 100 chewable tablets, and provides storage instructions. The label is distributed by Takeda Pharmaceuticals America, Inc. and includes an NDC number 59417-119-01 and a barcode.*

FDA Label Image

Principal Display Panel (60 mg Tablet Bottle Label)

Vyvanse 60 mg chewable tablets packaging label showing lisdexamfetamine dimesylate as the active ingredient. The label includes a 60 mg dosage strength, a white, oval chewable tablet image engraved with '60', and text indicating 100 chewable tablets per container. It advises chewing the tablets completely before swallowing. Distributed by Takeda Pharmaceuticals America, Inc., Lexington, MA.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.